Bisphosphonate Therapeutics in Bone Disease: The Hard and Soft Data on Osteoclast Inhibition
Matthew T. Drake and Serge C.L.M. Cremers
Mol Interv June 2010 10:141-152; doi:10.1124/mi.10.3.5
Strontium Ranelate in Osteoporosis and Beyond: Identifying Molecular Targets in Bone Cell Biology
Pierre J. Marie
Mol Interv October 2010 10:305-312; doi:10.1124/mi.10.5.7
Non-nuclear Actions of Estrogen: New Targets for Prevention and Treatment of Cardiovascular Disease
Karen J. Ho and James K. Liao
Mol Interv July 2002 2:219-228; doi:10.1124/mi.2.4.219
The “Heartbreak” of Older Age
Edward G. Lakatta and Steven J. Sollott
Mol Interv November 2002 2:431-446; doi:10.1124/mi.2.7.431
Phosphorylation of G Protein–Coupled Receptors: GPCR Kinases in Heart Disease
Jonathan A. Hata and Walter J. Koch
Mol Interv August 2003 3:264-272; doi:10.1124/mi.3.5.264
Low-Dose Aspirin, Coxibs, and other NSAIDS: A Clinical Mosaic Emerges
Carlo Patrono and Colin Baigent
Mol Interv February 2009 9:31-39; doi:10.1124/mi.9.1.8
Antioxidants in Hypertension and Cardiovascular Disease
Ernesto L. Schiffrin
Mol Interv December 2010 10:354-362; doi:10.1124/mi.10.6.4
Mechanism of Tissue-Selective Drug Action in the Cardiovascular System
Terrance D. Barrett, David J. Triggle, Michael J.A. Walker, and Donald H. Maurice
Mol Interv April 2005 5:84-93; doi:10.1124/mi.5.2.6
Antifibrillatory Agents and Potassium Channels in the Atria: Pore Block versus Channel Trafficking
Dyke P. McEwen and Jeffrey R. Martens
Mol Interv April 2009 9:79-86; doi:10.1124/mi.9.2.7
The Cardiotoxicology of Anthracycline Chemotherapeutics: Translating Molecular Mechanism Into Preventative Medicine
Xuyang Peng, Billy Chen, Chee Chew Lim, and Douglas B. Sawyer
Mol Interv June 2005 5:163-171; doi:10.1124/mi.5.3.6
Na+-K+–ATPase-Mediated Signal Transduction: From Protein Interaction to Cellular Function
Zijian Xie and Ting Cai
Mol Interv May 2003 3:157-168; doi:10.1124/mi.3.3.157
Vasomotion: Mechanisms and Physiological Importance
Holger Nilsson and Christian Aalkjær
Mol Interv March 2003 3:79-89; doi:10.1124/mi.3.2.79
RHO Signaling in Vascular Diseases
Tammy M. Seasholtz and Joan Heller Brown
Mol Interv December 2004 4:348-357; doi:10.1124/mi.4.6.8
Secretory Functions of Smooth Muscle: Cytokines and Growth Factors
William T. Gerthoffer and Cherie A. Singer
Mol Interv November 2002 2:447-456; doi:10.1124/mi.2.7.447
Fibrin Mechanisms and Functions in Nervous System Pathology
Ryan A. Adams, Melissa Passino, Benjamin D. Sachs, Tal Nuriel, and Katerina Akassoglou
Mol Interv June 2004 4:163-176; doi:10.1124/mi.4.3.6
Estrogen and Mitochondria: A New Paradigm for Vascular Protection?
Sue Piper Duckles, Diana N. Krause, Christopher Stirone, and Vincent Procaccio
Mol Interv February 2006 6:26-35; doi:10.1124/mi.6.1.6
Advanced Drug Delivery Systems That Target The Vascular Endothelium
Bi-Sen Ding, Thomas Dziubla, Vladimir V. SSilvia Muro, and Vladimir R. Muzykantov
Mol Interv April 2006 6:98-112; doi:10.1124/mi.6.2.7
Molecular Mechanisms of SERT in Platelets: Regulation of Plasma Serotonin Levels
Charles P. Mercado and Fusun Kilic
Mol Interv August 2010 10:231-241; doi:10.1124/mi.10.4.6
NOX Isoforms and Reactive Oxygen Species in Vascular Health
Rhian M. Touyz, Ana M. Briones, Mona Sedeek, Dylan Burger, and Augosto C. Montezano
Mol Interv February 2011 11:27-35; doi:10.1124/mi.11.1.5
Proteases Display Biased Agonism at Protease-Activated Receptors: Location matters!
Angela Russo, Unice J. K. Soh, and JoAnn Trejo
Mol Interv April 2009 9:87-96; doi:10.1124/mi.9.2.8